Recent international literature characterizing the costs of illness for asthma care has led to a better understanding of the economic impact of this condition. In addition, health economic studies in this area have begun to define the cost-effectiveness of key intervention strategies for individuals with moderate and severe clinical expressions of this condition. Currently, however, there is little information related to the health economics of mild asthma. The purpose of this report is to provide a brief overview of the issues related to the health economics of asthma, with a particular focus on persons with mild morbidity. This overview will address the cost-of-illness for asthma as well as some of the theoretical models for developing the health economic evaluations of clinical interventions for asthma. The literature suggests that clinical trials are needed in order to best understand the health economic issues in mild asthma. These trials should examine interventions specifically targeted to individuals with mild asthma and should include clinically relevant outcomes such as 'symptom-free days' as well as relatively long observational periods (3-5 yrs). Whilst clinical trials should be the basis for determining optimal clinical intervention strategies for mild asthma, short-term knowledge may be gained from economic modelling and the few studies of the natural history of asthma that presently exist.
|Original language||English (US)|
|Number of pages||5|
|Journal||European Respiratory Review|
|State||Published - Jan 1 1996|
- Cost of illness
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine